DTX401 Gene Therapy in Glycogen Storage Disease (GSD) Type Ia

DTX401 Gene Therapy in Glycogen Storage Disease (GSD) Type Ia

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description
Our team at the Congenital Hyperinsulinism Center at CHOP is working on a research study to determine whether an experimental gene therapy product, DTX401, is safe and effective in people with glycogen storage disease type Ia (GSDIa). The FDA has not approved this drug for the treatment of GSDIa but has approved us to use this drug as part of this clinical trial. The purpose of this research study is to see if DTX401 can help people with GSDIa have normal blood sugar levels and fewer episodes of hypoglycemia. DTX041 works by delivering copies of the G6PC gene to your liver through a one-time infusion. Participation in this study will last for 2 years and will involve 30 study visits. It is possible that treatment with the study drug infusion may improve your blood sugar levels. Travel costs will be covered by the study and you will receive compensation for participating.

Eligibility and criteria
IRB Number:
21-018683
Eligible age range:
8 years - 99 years
Clinical trial phase:
Phase III
Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer Of Glucose-6-Phosphatase In Patients With Glycogen Storage Disease Type Ia

What to expect


Related specialties

Related conditions
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.